Nasta, Nafiza .
HRN: 15-10-33 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/30/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
09/30/2025
10/07/2025
IV
600mg
Q8
Infected Wound Breast, Right
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes